A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
NCT07135466
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER_GOV
Sponsor class
Conditions
B Cell Malignancies
Interventions
OTHER:
CD22 CAR-T cells
Sponsor
Sheba Medical Center